T1	Pregnancy_considerations 0 207	Pregnant women and nursing mothers are ineligible due to the possible risk of adverse effects in the newborn. Eligible patients of reproductive potential should use adequate contraception if sexually active.
T2	Post-eligibility 209 369	Serious concurrent medical illness which would jeopardize the ability of the subject to receive the therapy as outlined in this protocol with reasonable safety.
T3	Condition 371 381	Malignancy
T4	Temporal 403 417	within 5 years
R1	Has_temporal Arg1:T3 Arg2:T4	
T5	Procedure 436 445	treatment
T6	Qualifier 426 435	localized
T7	Temporal 419 425	recent
T8	Condition 449 457;480 496	squamous cell skin cancer
T9	Condition 461 496	non-invasive basal cell skin cancer
*	OR T9 T8
T10	Negation 501 510	permitted
T11	Scope 449 496	squamous or non-invasive basal cell skin cancer
R2	Has_scope Arg1:T5 Arg2:T11	
R3	Has_qualifier Arg1:T5 Arg2:T6	
R4	Has_negation Arg1:T5 Arg2:T10	
T12	Condition 512 538	cervical carcinoma in situ
T13	Negation 542 549	allowed
T14	Procedure 567 574	treated
T15	Qualifier 553 566	appropriately
R5	Has_qualifier Arg1:T14 Arg2:T15	
T16	Temporal 575 593	prior to screening
R6	Has_temporal Arg1:T14 Arg2:T16	
R7	AND Arg1:T12 Arg2:T14	
R8	Has_negation Arg1:T12 Arg2:T13	
T17	Non-representable 596 656	subjects under evaluation for a malignancy are not eligible.
T18	Condition 673 696	hepatitis B virus (HBV)
T19	Condition 700 734	human immunodeficiency virus (HIV)
*	OR T18 T19
T20	Post-eligibility 736 825	Use of any prohibited concomitant medications within 30 days of the Baseline/Day 1 visit.
T21	Condition 833 849	hypersensitivity
T22	Drug 853 856	LDV
T23	Drug 857 860	SOF
*	OR T22 T23
T24	Scope 853 860	LDV/SOF
R9	Has_scope Arg1:T21 Arg2:T24	
